Johnson & Johnson

Johnson & Johnson (J&J) is one of the world's largest and most established healthcare corporations, headquartered in New Brunswick, New Jersey. Founded in 1886, the company has long been a staple of the global medical landscape, operating through divisions focused on pharmaceuticals, medical devices, and—until a recent corporate spin-off—consumer health products. For the Israeli market and the broader Jewish world, J&J represents a critical node in the global supply chain for essential medicines and surgical equipment, maintaining a significant presence in Israel's healthcare ecosystem through local distribution and research collaborations.

In recent years, the company's reputation and financial standing have been heavily impacted by large-scale litigation in the United States. The most prominent of these legal challenges involves claims that the company’s talc-based baby powder was contaminated with asbestos, allegedly leading to ovarian cancer and mesothelioma in long-term users. While J&J has consistently maintained the safety of its products, it has moved toward multi-billion dollar settlements to resolve tens of thousands of pending lawsuits and provide certainty to its shareholders.

Beyond its consumer product controversies, J&J remains a leader in medical innovation. Its pharmaceutical arm, Janssen, was instrumental during the COVID-19 pandemic as the developer of a single-shot vaccine. For The Zioneer Intelligence Desk, monitoring J&J is essential not only due to its economic weight but also because of its role in the global pharmaceutical industry, which directly affects Israeli public health policy and the stability of international medical markets.